Receipt of Recommended Follow-up Care After a Positive Lung Cancer Screening Examination
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.40403
Abstract: Key Points Question What are the rates and factors associated with adherence to recommended follow-up and adherence after an extended timeline following a positive lung cancer screening examination? Findings In this cohort study of 685… read more here.
Keywords: positive lung; lung cancer; screening examination; cancer screening ... See more keywords
Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer.
Sign Up to like & getrecommendations! Published in 2020 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.9b00378
Abstract: We report on the synergistic effect of PI3K inhibition with ALK inhibition for the possible treatment of EML4-ALK positive lung cancer. We have brought together ceritinib (ALK inhibitor) and pictilisib (PI3K inhibitor) into a single… read more here.
Keywords: positive lung; alk; alk positive; lung cancer ... See more keywords
Disparities in Follow-up After Low-Dose Lung Cancer Screening.
Sign Up to like & getrecommendations! Published in 2019 at "Seminars in thoracic and cardiovascular surgery"
DOI: 10.1053/j.semtcvs.2019.10.006
Abstract: The National Lung Cancer Screening Trial (NLST) demonstrated an improvement in overall survival with lung cancer screening. Achieving follow-up for a positive screen is essential to impact early intervention for lung cancer. The objective of… read more here.
Keywords: status; positive lung; cancer screening; lung cancer ... See more keywords
Qualitative and quantitative cytomorphological features of primary anaplastic lymphoma kinase‐positive lung cancer
Sign Up to like & getrecommendations! Published in 2019 at "Cytopathology"
DOI: 10.1111/cyt.12667
Abstract: Anaplastic lymphoma kinase (ALK) positive (+) lung cancers are predictive for response to crizotinib and alectinib. There are many cases of lung cancer in which surgery cannot be performed, and such cases require diagnosis by… read more here.
Keywords: lymphoma kinase; positive lung; anaplastic lymphoma; lung cancer ... See more keywords
PET positive lung mass in a patient with rectal cancer
Sign Up to like & getrecommendations! Published in 2021 at "BMJ Case Reports"
DOI: 10.1136/bcr-2021-244055
Abstract: To cite: Saha S, Chong WH, Bonnier A, et al. BMJ Case Rep 2021;14:e244055. doi:10.1136/bcr-2021244055 Internal Medicine, Bangladesh Medical College, Dhaka, Bangladesh Pulmonary and Critical Care Medicine, Albany Medical Center, Albany, New York, USA Department… read more here.
Keywords: medicine; mass patient; positive lung; pet positive ... See more keywords
Abstract LB259: Distinct microRNA signature and suppression of ZFP36L1 define ASCL1-positive lung adenocarcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-lb259
Abstract: Background: Achaete-scute family bHLH transcription factor 1 (ASCL1) is a master transcription factor involved in neuroendocrine differentiation. ASCL1 is expressed in approximately 10% of lung adenocarcinomas and exerts tumor-promoting effects. However, microRNA (miRNA) profiles regulated… read more here.
Keywords: lung adenocarcinoma; ascl1 positive; positive lung; lung ... See more keywords
Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma
Sign Up to like & getrecommendations! Published in 2020 at "Therapeutics and Clinical Risk Management"
DOI: 10.2147/tcrm.s229860
Abstract: Abstract A 75-year-old woman was diagnosed with c-ros oncogene 1 (ROS1)-positive lung adenocarcinoma. She was treated with crizotinib 750 mg/day for 4.5 years, with partial tumor response. However, the patient subsequently presented with right hip… read more here.
Keywords: ros1 positive; lung adenocarcinoma; positive lung; patient ... See more keywords
Lorlatinib as a treatment for ALK-positive lung cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Future oncology"
DOI: 10.2217/fon-2022-0184
Abstract: Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, has been approved as a treatment for ALK-positive lung cancer. This review provides information regarding the pharmacology and clinical features of lorlatinib, including its efficacy and associated adverse… read more here.
Keywords: positive lung; lung cancer; treatment alk; alk positive ... See more keywords